Heterogeneity of Immune Control in Chronic Hepatitis B Virus Infection: Clinical Implications on Immunity with Interferon-α Treatment and Retreatment

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Nov 10

PMID 36353205

Authors

Guo-Qing Yin

Ke-Ping Chen

Xiao-Chun Gu

Affiliations

Soon will be listed here.

Abstract

Hepatitis B virus (HBV) infection is a global public health issue. Interferon-α (IFN-α) treatment has been used to treat hepatitis B for over 20 years, but fewer than 5% of Asians receiving IFN-α treatment achieve functional cure. Thus, IFN-α retreatment has been introduced to enhance antiviral function. In recent years, immune-related studies have found that the complex interactions between immune cells and cytokines could modulate immune response networks, in-cluding both innate and adaptive immunity, triggering immune responses that control HBV replication. However, heterogeneity of the immune system to control HBV infection, particularly HBV-specific CD8 T cell heterogeneity, has consequ-ential effects on T cell-based immunotherapy for treating HBV infection. Altogether, the host's genetic variants, negative-feedback regulators and HBV components affecting the immune system's ability to control HBV. In this study, we reviewed the literature on potential immune mechanisms affecting the immune control of HBV and the clinical effects of IFN-α treatment and retreatment.

Citing Articles

Evaluation of reverse transcription-polymerase chain reaction and simultaneous amplification and testing for quantitative detection of serum hepatitis B virus RNA.

Hu X, Zhao L, Ou M, Chen Y, Wei H, Xia Y Heliyon. 2023; 9(8):e18557.

PMID: 37560627 PMC: 10407120. DOI: 10.1016/j.heliyon.2023.e18557.

References

McLane L, Abdel-Hakeem M, Wherry E . CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol. 2019; 37:457-495. DOI: 10.1146/annurev-immunol-041015-055318. View

Ma Z, Cao Q, Xiong Y, Zhang E, Lu M . Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B. Vaccines (Basel). 2018; 6(1). PMC: 5874647. DOI: 10.3390/vaccines6010006. View

Martinez M, Testoni B, Zoulim F . Biological basis for functional cure of chronic hepatitis B. J Viral Hepat. 2019; 26(7):786-794. DOI: 10.1111/jvh.13090. View

Han J, Shin E . Liver-Resident Memory CD8 T Cells: Possible Roles in Chronic HBV Infection. Int J Mol Sci. 2021; 22(1). PMC: 7795050. DOI: 10.3390/ijms22010283. View

Ji M, Hu K . Recent advances in the study of hepatitis B virus covalently closed circular DNA. Virol Sin. 2017; 32(6):454-464. PMC: 6598884. DOI: 10.1007/s12250-017-4009-4. View

Saxena R, Chawla Y, Verma I, Kaur J . Effect of IL-12B, IL-2, TGF-β1, and IL-4 polymorphism and expression on hepatitis B progression. J Interferon Cytokine Res. 2013; 34(2):117-28. DOI: 10.1089/jir.2013.0043. View

OBrien T, Yang H, Groover S, Jeng W . Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology. 2018; 156(2):400-417. DOI: 10.1053/j.gastro.2018.09.052. View

Gehring A, Protzer U . Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology. 2018; 156(2):325-337. DOI: 10.1053/j.gastro.2018.10.032. View

Salimzadeh L, Bert N, Dutertre C, Gill U, Newell E, Frey C . PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018; 128(10):4573-4587. PMC: 6159957. DOI: 10.1172/JCI121957. View

10.

Chang M, Liaw Y . Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses. Int J Mol Sci. 2022; 23(3). PMC: 8836007. DOI: 10.3390/ijms23031552. View

11.

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

12.

Wasityastuti W, Yano Y, Ratnasari N, Triyono T, Triwikatmani C, Indrarti F . Protective effects of HLA-DPA1/DPB1 variants against Hepatitis B virus infection in an Indonesian population. Infect Genet Evol. 2016; 41:177-184. DOI: 10.1016/j.meegid.2016.03.034. View

13.

Liang T, Block T, McMahon B, Ghany M, Urban S, Guo J . Present and future therapies of hepatitis B: From discovery to cure. Hepatology. 2015; 62(6):1893-908. PMC: 4681668. DOI: 10.1002/hep.28025. View

14.

Lang J, Neumann-Haefelin C, Thimme R . Immunological cure of HBV infection. Hepatol Int. 2019; 13(2):113-124. DOI: 10.1007/s12072-018-9912-8. View

15.

Goh Z, Ren E, Ko H . Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B. World J Gastroenterol. 2021; 27(14):1369-1391. PMC: 8047536. DOI: 10.3748/wjg.v27.i14.1369. View

16.

He D, Tao S, Guo S, Li M, Wu J, Huang H . Interaction of TLR-IFN and HLA polymorphisms on susceptibility of chronic HBV infection in Southwest Han Chinese. Liver Int. 2014; 35(8):1941-9. PMC: 6680266. DOI: 10.1111/liv.12756. View

17.

Kim W, Lee S, Son Y, Ko C, Ryu W . DDB1 Stimulates Viral Transcription of Hepatitis B Virus via HBx-Independent Mechanisms. J Virol. 2016; 90(21):9644-9653. PMC: 5068517. DOI: 10.1128/JVI.00977-16. View

18.

Yin G, Zhong B . Efficacy of interferon for chronic hepatitis B in patients with nucleoside and nucleotide combination therapy failure. J Gastroenterol Hepatol. 2015; 31(1):248-55. DOI: 10.1111/jgh.13191. View

19.

Megahed F, Zhou X, Sun P . The Interactions between HBV and the Innate Immunity of Hepatocytes. Viruses. 2020; 12(3). PMC: 7150781. DOI: 10.3390/v12030285. View

20.

Tan A, Loggi E, Boni C, Chia A, Gehring A, Sastry K . Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol. 2008; 82(22):10986-97. PMC: 2573267. DOI: 10.1128/JVI.01124-08. View